SI2935222T1 - Inhibitorji PRMT5 in njihove uporabe - Google Patents
Inhibitorji PRMT5 in njihove uporabeInfo
- Publication number
- SI2935222T1 SI2935222T1 SI201331283T SI201331283T SI2935222T1 SI 2935222 T1 SI2935222 T1 SI 2935222T1 SI 201331283 T SI201331283 T SI 201331283T SI 201331283 T SI201331283 T SI 201331283T SI 2935222 T1 SI2935222 T1 SI 2935222T1
- Authority
- SI
- Slovenia
- Prior art keywords
- prmt5 inhibitors
- prmt5
- inhibitors
- Prior art date
Links
- 101100434927 Caenorhabditis elegans prmt-5 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
- C12N9/1007—Methyltransferases (general) (2.1.1.)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261745485P | 2012-12-21 | 2012-12-21 | |
US201361790525P | 2013-03-15 | 2013-03-15 | |
EP13821599.1A EP2935222B1 (en) | 2012-12-21 | 2013-12-20 | Prmt5 inhibitors and uses thereof |
PCT/US2013/077235 WO2014100719A2 (en) | 2012-12-21 | 2013-12-20 | Prmt5 inhibitors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2935222T1 true SI2935222T1 (sl) | 2019-02-28 |
Family
ID=49958717
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI201331283T SI2935222T1 (sl) | 2012-12-21 | 2013-12-20 | Inhibitorji PRMT5 in njihove uporabe |
Country Status (30)
Country | Link |
---|---|
US (10) | US9604930B2 (sl) |
EP (3) | EP3498701B1 (sl) |
JP (1) | JP6678455B2 (sl) |
KR (2) | KR102024417B1 (sl) |
CN (1) | CN105452226B (sl) |
AU (1) | AU2018202150B2 (sl) |
BR (1) | BR112015014590B1 (sl) |
CA (1) | CA2894228C (sl) |
CL (1) | CL2015001790A1 (sl) |
CR (1) | CR20150371A (sl) |
CY (1) | CY1121625T1 (sl) |
DK (1) | DK2935222T3 (sl) |
DO (1) | DOP2015000158A (sl) |
EA (1) | EA027908B1 (sl) |
ES (1) | ES2701069T3 (sl) |
HK (1) | HK1212690A1 (sl) |
HR (1) | HRP20182037T1 (sl) |
HU (1) | HUE040323T2 (sl) |
IL (3) | IL239296B (sl) |
LT (1) | LT2935222T (sl) |
MX (1) | MX2015008052A (sl) |
PE (1) | PE20151501A1 (sl) |
PH (2) | PH12015501351A1 (sl) |
PL (1) | PL2935222T3 (sl) |
PT (1) | PT2935222T (sl) |
RS (1) | RS58040B1 (sl) |
SI (1) | SI2935222T1 (sl) |
UA (1) | UA118548C2 (sl) |
WO (1) | WO2014100719A2 (sl) |
ZA (1) | ZA201505212B (sl) |
Families Citing this family (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012170904A2 (en) * | 2011-06-10 | 2012-12-13 | Bytemobile, Inc. | Adaptive bitrate management on progressive download with indexed media files |
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
EP2935240A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
KR102327888B1 (ko) | 2012-12-21 | 2021-11-17 | 얀센 바이오파마, 인코퍼레이트. | 치환된 뉴클레오사이드, 뉴클레오타이드 및 그것의 유사체 |
EP3498701B1 (en) | 2012-12-21 | 2023-02-22 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
JP6554037B2 (ja) | 2013-01-15 | 2019-07-31 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物 |
EP2970220A2 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
KR102158756B1 (ko) | 2013-03-14 | 2020-09-23 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9045455B2 (en) | 2013-03-14 | 2015-06-02 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
EP2970137A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
KR20160003647A (ko) | 2013-03-15 | 2016-01-11 | 에피자임, 인코포레이티드 | Carm1 억제제 및 이의 용도 |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US9556197B2 (en) | 2013-08-23 | 2017-01-31 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
EP3521285A1 (en) | 2014-06-17 | 2019-08-07 | Pfizer Inc | Substituted dihydroisoquinolinone compounds |
CR20160598A (es) | 2014-06-25 | 2017-03-10 | Glaxosmithkline Intelectual Property Dev Ltd | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il) amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil) pirimidino-4-carboxamida |
EP3160477A4 (en) * | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2015200677A2 (en) * | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
CA2953572A1 (en) * | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2016034671A1 (en) * | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
EP3189041B1 (en) * | 2014-09-03 | 2021-04-28 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
US10479997B2 (en) | 2014-12-01 | 2019-11-19 | Novartis Ag | Compositions and methods for diagnosis and treatment of prostate cancer |
AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
TW202321249A (zh) * | 2015-08-26 | 2023-06-01 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
CN105497034B (zh) * | 2015-12-08 | 2018-08-07 | 暨南大学 | 一种通过靶向prmt5抑制骨肉瘤生长的组合物及其制备方法 |
GB201604029D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604020D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604022D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604030D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604031D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
GB201604027D0 (en) | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
CA3016096C (en) | 2016-03-10 | 2023-10-17 | Janssen Pharmaceutica Nv | Substituted nucleoside analogues for use as prmt5 inhibitors |
EA201892031A1 (ru) | 2016-03-10 | 2019-02-28 | Янссен Фармацевтика Нв | Замещенные аналоги нуклеозидов для применения в качестве ингибиторов prmt5 |
CA2969295A1 (en) * | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
BR112019004691A2 (pt) | 2016-09-14 | 2019-06-25 | Janssen Pharmaceutica Nv | inibidores bicíclicos em espiro da interação menina-mll |
AU2017326485B2 (en) | 2016-09-14 | 2021-04-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
MA46341A (fr) | 2016-10-03 | 2019-08-07 | Janssen Pharmaceutica Nv | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
EA201991071A1 (ru) | 2016-10-28 | 2019-11-29 | Композиции и способы для лечения ezh2-опосредованного рака | |
US11197857B2 (en) | 2016-12-01 | 2021-12-14 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
KR20190090823A (ko) * | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 조합 요법 |
EP3551185A4 (en) | 2016-12-08 | 2021-07-14 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS OF TREATMENT OF CDK4 / 6 MEDIATED CANCER |
US10745409B2 (en) | 2016-12-15 | 2020-08-18 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
UA127679C2 (uk) | 2017-02-27 | 2023-11-29 | Янссен Фармацевтика Нв | Спосіб ідентифікації пацієнта, що характеризується наявністю сприйнятливості до лікування недрібноклітинного раку легені інгібітором prmt5 |
WO2018161922A1 (zh) * | 2017-03-09 | 2018-09-13 | 中国科学院上海药物研究所 | 一种具有prmt5抑制活性的化合物及其制备和应用 |
GB201704327D0 (en) * | 2017-03-17 | 2017-05-03 | Argonaut Therapeutics Ltd | Compounds |
KR20200036922A (ko) * | 2017-08-09 | 2020-04-07 | 프렐루드 테라퓨틱스, 인코포레이티드 | 단백질 아르기닌 메틸트랜스퍼라제 5 (prmt5)의 선택적 억제제 |
CN111108105B (zh) | 2017-09-22 | 2023-03-31 | 朱比兰特埃皮帕德有限公司 | 作为pad抑制剂的杂环化合物 |
PT3697785T (pt) | 2017-10-18 | 2023-04-03 | Jubilant Epipad LLC | Compostos de imidazopiridina como inibidores de pad |
KR20200085836A (ko) | 2017-11-06 | 2020-07-15 | 주빌런트 프로델 엘엘씨 | Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체 |
US10947234B2 (en) * | 2017-11-08 | 2021-03-16 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
CA3083374A1 (en) * | 2017-11-24 | 2019-05-31 | Jubilant Episcribe Llc | Heterocyclic compounds as prmt5 inhibitors |
EP3720865B1 (en) | 2017-12-08 | 2024-03-13 | Janssen Pharmaceutica NV | Novel spirobicyclic analogues |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2019116302A1 (en) | 2017-12-13 | 2019-06-20 | Lupin Limited | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
EP3755317A4 (en) * | 2018-02-22 | 2022-02-23 | Icahn School of Medicine at Mount Sinai | COMPOUNDS DEGRADING/DESTRUCTING PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) AND METHODS OF USE |
AU2019231689A1 (en) | 2018-03-06 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (AKT) degradation / disruption compounds and methods of use |
CA3090836C (en) | 2018-03-09 | 2024-04-16 | Pharmablock Sciences (Nanjing), Inc. | 3,4-dihydroisoquinolin-2(1h)-yl derivates useful as inhibitors of protein arginine methyltransferase 5 (prmt5), and pharmaceutical products thereof |
EP3765453A1 (en) | 2018-03-13 | 2021-01-20 | Jubilant Prodel LLC | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation |
US11365205B2 (en) | 2018-03-22 | 2022-06-21 | Aurigene Discovery Technologies Limited | Imidazolidin-2-one compounds as PRMT5 modulators |
KR20200135827A (ko) * | 2018-03-22 | 2020-12-03 | 오리진 디스커버리 테크놀로지스 리미티드 | Prmt5 억제제로서 치환된 이미다졸리딘-2-온 유도체 |
WO2019219805A1 (en) | 2018-05-16 | 2019-11-21 | Ctxone Pty Ltd | Combination therapy |
US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
CA3118175A1 (en) * | 2018-11-08 | 2020-05-14 | Glaxosmithkline Intellectual Property Development Limited | Combination of prmt5 inhibitors and bcl-2 inhibitors |
WO2020182018A1 (zh) * | 2019-03-12 | 2020-09-17 | 四川科伦博泰生物医药股份有限公司 | 氮杂环化合物、其制备方法及用途 |
WO2020205660A1 (en) * | 2019-03-29 | 2020-10-08 | University Of Florida Research Foundation, Incorporated | Prmt5 inhibitor compounds |
CN111825656B (zh) * | 2019-04-15 | 2023-03-31 | 南京药石科技股份有限公司 | 蛋白质精氨酸甲基转移酶5(prmt5)的抑制剂、其药学产品及其方法 |
TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用prmt5抑制劑治療癌症之方法 |
HRP20231673T1 (hr) | 2019-06-10 | 2024-03-15 | Lupin Limited | Inhibitori prmt5 |
MA56185A (fr) | 2019-06-12 | 2022-04-20 | Janssen Pharmaceutica Nv | Nouveaux intermédiaires spirobicycliques |
CN114126651A (zh) | 2019-06-28 | 2022-03-01 | Als治疗发展学会 | 对二肽重复蛋白的抑制 |
CN110585434B (zh) * | 2019-10-11 | 2021-04-09 | 山东大学 | Prmt5抑制剂在抗病毒中的应用 |
KR20220080160A (ko) | 2019-10-12 | 2022-06-14 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | Prmt5 억제제로서의 치환 삼환류 화합물 및 그의 응용 |
JP2023504230A (ja) | 2019-10-22 | 2023-02-02 | ルピン・リミテッド | Prmt5阻害剤の組合せ医薬 |
CN112778275B (zh) * | 2019-11-11 | 2023-05-12 | 石药集团中奇制药技术(石家庄)有限公司 | 金刚烷基prmt5抑制剂及其应用 |
CN110950841A (zh) * | 2019-11-22 | 2020-04-03 | 济南大学 | 一类新型三唑类化合物的合成及应用 |
CN111018832A (zh) * | 2019-11-26 | 2020-04-17 | 济南大学 | 一类含有四氢异喹啉结构的咪唑酮类化合物的制备及应用 |
KR102514245B1 (ko) * | 2019-12-03 | 2023-03-29 | 한양대학교 에리카산학협력단 | 단백질 인산화 효소 저해 활성을 갖는 신규한 피라졸 유도체 및 이의 용도 |
CN115135651A (zh) | 2019-12-03 | 2022-09-30 | 鲁皮恩有限公司 | 作为prmt5抑制剂的被取代的核苷类似物 |
AU2020408148A1 (en) * | 2019-12-17 | 2022-06-16 | Merck Sharp & Dohme Llc | PRMT5 inhibitors |
EP4076459A4 (en) * | 2019-12-17 | 2023-12-20 | Merck Sharp & Dohme LLC | PRMT5 INHIBITORS |
CN113045543B (zh) * | 2019-12-26 | 2023-05-12 | 石药集团中奇制药技术(石家庄)有限公司 | 一种prmt5抑制剂及其应用 |
KR20230012041A (ko) * | 2020-06-02 | 2023-01-25 | 씨에스피씨 종콰이 팔마씨우티컬 테크놀로지 (스자좡) 컴퍼니 리미티드 | 3,4-디하이드로이소퀴놀린계 화합물 및 그 사용 |
CN113754541A (zh) * | 2020-06-02 | 2021-12-07 | 深圳湾实验室 | 靶向eb病毒核抗原蛋白的小分子抑制剂、制备方法及其应用 |
CN111592522B (zh) * | 2020-06-17 | 2022-09-09 | 郑州大学 | 一种精氨酸甲基化转移酶5小分子抑制剂及其制备方法和用途 |
CN116568677A (zh) | 2020-07-31 | 2023-08-08 | 探戈医药股份有限公司 | 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物 |
WO2022048631A1 (zh) * | 2020-09-04 | 2022-03-10 | 上海翊石医药科技有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
CN116134034A (zh) * | 2020-09-22 | 2023-05-16 | 南京明德新药研发有限公司 | 四氢异喹啉衍生物及其应用 |
JP2024517495A (ja) | 2021-05-13 | 2024-04-22 | イノブストーン セラピューティクス リミテッド | 抗腫瘍活性を有する化合物及びその使用 |
GB202117230D0 (en) | 2021-11-29 | 2022-01-12 | Argonaut Therapeutics Ltd | Peptide vaccine |
CN116867491A (zh) * | 2021-12-08 | 2023-10-10 | 石药集团中奇制药技术(石家庄)有限公司 | 3,4-二氢异喹啉类化合物的盐及其应用 |
GB202203588D0 (en) | 2022-03-15 | 2022-04-27 | Argonaut Therapeutics Ltd | Cancer diagnostic |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE63776C (de) | A. RUPERT, Eisenbahn - Werkmeister, in Köln - Nippes, Escherstrafse 14 | Verfahren und Vorrichtung eiserne Rohrwände mit Messing zu überziehen | ||
DD68906A (sl) | ||||
GB1374366A (en) | 1972-07-21 | 1974-11-20 | Science Union & Cie | Propanol derivatives and a process for their preparation |
DE2361390A1 (de) * | 1973-12-10 | 1975-06-19 | Merck Patent Gmbh | Isochinolinderivate und verfahren zu ihrer herstellung |
US4022776A (en) | 1974-01-31 | 1977-05-10 | Otsuka Pharmaceutical Company Limited | 5-[1-Hydroxy-2-(substituted-amino)]ethyl-8-hydroxycarbostyril derivatives |
CA1072359A (en) | 1974-10-08 | 1980-02-26 | Hiroyuki Konishi | Method for controlling the growth of plants |
HU179951B (en) | 1979-10-11 | 1983-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing 1,2,4-oxadiazolin-5-one derivatives and pharmaceutical compositions containing thereof |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
FI832173L (fi) | 1982-06-16 | 1983-12-17 | May & Baker Ltd | Foerfarande foer framstaellning av ett terapeutiskt anvaendbart pyrazolopyridinderivat |
DE3303344A1 (de) | 1983-02-02 | 1984-08-02 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten aminosaeuren und deren estern |
US4684459A (en) | 1985-11-29 | 1987-08-04 | The Dow Chemical Company | Collector compositions for the froth flotation of mineral values |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
JPH07100688B2 (ja) * | 1986-02-12 | 1995-11-01 | 大日本製薬株式会社 | 環状アミン誘導体 |
DE3631013A1 (de) * | 1986-09-12 | 1988-03-24 | Thomae Gmbh Dr K | Neue naphthylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE3640641A1 (de) | 1986-11-28 | 1988-07-14 | Thomae Gmbh Dr K | Neue heteroaromatische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
DE3804793A1 (de) | 1988-02-16 | 1989-08-24 | Hoechst Ag | Renin-hemmende aminosaeurederivate |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
DE3839126A1 (de) | 1988-11-19 | 1990-05-23 | Hoechst Ag | Renin-hemmende harnstoffderivate von dipeptiden, verfahren zu deren herstellung, diese enthaltende mittel und ihre verwendung |
US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
GB9005318D0 (en) | 1990-03-09 | 1990-05-02 | Isis Innovation | Antiarrhythmic agents |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
WO1993001174A1 (en) | 1991-07-08 | 1993-01-21 | Glaxo Group Limited | Thiazolidine derivatives and their use as anti-viral compounds |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
AU4567193A (en) | 1992-07-10 | 1994-01-31 | Laboratoires Glaxo S.A. | Anilide derivatives |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5514694A (en) | 1992-09-21 | 1996-05-07 | Georgia Tech Research Corp | Peptidyl ketoamides |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5294621A (en) | 1992-10-07 | 1994-03-15 | Ortho Pharmaceutical Corporation | Thieno tetrahydropyridines useful as class III antiarrhythmic agents |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
GB9402807D0 (en) * | 1994-02-14 | 1994-04-06 | Xenova Ltd | Pharmaceutical compounds |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5693847A (en) | 1995-04-19 | 1997-12-02 | Vertex Pharmaceuticals Incorporated | Heteroatom functionalized α-methyl ketones |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5554621A (en) * | 1995-06-07 | 1996-09-10 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: nitrogen heterocyclic derivatives |
US6130217A (en) | 1995-09-20 | 2000-10-10 | Pfizer Inc | Compounds enhancing antitumor activity of other cytotoxic agents |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
SE9600769D0 (sv) | 1996-02-28 | 1996-02-28 | Astra Ab | Compounds useful as analgesic |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
GB9717576D0 (en) | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
US5874449A (en) | 1996-12-31 | 1999-02-23 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US20020169101A1 (en) | 1999-05-10 | 2002-11-14 | Gonzalez Maria Isabel | Treatment of sexual dysfunction |
CA2373279A1 (en) * | 1999-05-25 | 2000-12-14 | The Penn State Research Foundation | Dna methyltransferase inhibitors |
US7253165B2 (en) | 1999-09-14 | 2007-08-07 | Aventis Pharmaceuticals Inc. | Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists |
DK1216244T3 (da) | 1999-09-14 | 2003-11-17 | Aventis Pharma Inc | Benzisoxazolyl-, pyridoisoxazolyl- og benzothienylphenoxyderivater som D4-antagonister |
US7125903B1 (en) | 1999-09-14 | 2006-10-24 | Aventis Pharmaceuticals Inc. | Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists |
ES2209995T3 (es) | 1999-09-14 | 2004-07-01 | Aventis Pharmaceuticals Inc. | Derivados de propilo sustituidos con tienoisoxazolil- y tienopirrazolil-fenoxi, utiles en calidad de antagonistas d4. |
KR100842698B1 (ko) | 2000-03-14 | 2008-07-01 | 액테리온 파마슈티칼 리미티드 | 1,2,3,4-테트라하이드로이소퀴놀린 유도체 |
AU2001277728A1 (en) | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
ATE300533T1 (de) * | 2001-03-27 | 2005-08-15 | Actelion Pharmaceuticals Ltd | 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten |
EP1409450B1 (en) | 2001-07-11 | 2009-12-09 | Elan Pharmaceuticals, Inc. | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
MXPA04001773A (es) | 2001-08-27 | 2004-05-31 | Arpida Ag | Derivados de 6,7-dihidroxitetrahidroisquinolinas 3-sustituidas parta uso como agentes antibacterianos. |
TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
SE0103644D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic isoquinoline compounds |
TW200304808A (en) | 2001-11-08 | 2003-10-16 | Elan Pharm Inc | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
US7338969B2 (en) | 2002-03-08 | 2008-03-04 | Quonova, Llc | Modulation of pathogenicity |
US7335779B2 (en) | 2002-03-08 | 2008-02-26 | Quonova, Llc | Modulation of pathogenicity |
AU2003215024B2 (en) | 2002-03-26 | 2008-02-21 | Merck Sharp & Dohme Corp. | Spirocyclic amides as cannabinoid receptor modulators |
EP1494997A4 (en) | 2002-04-05 | 2007-04-11 | Merck & Co Inc | SUBSTITUTED ARYLAMID |
US8013014B2 (en) | 2002-07-05 | 2011-09-06 | Georgia Tech Research Corporation | Aza-peptide epoxides |
RS20050208A (en) | 2002-09-09 | 2007-08-03 | Janssen Pharmaceutica N.V., | Hydroxy alkyl substituted 1,3,8- triazaspiro/4,5/decan-4- one derivatives useful for the treatment of orl-1 receptor mediated disorders |
SE0300010D0 (sv) | 2003-01-07 | 2003-01-07 | Astrazeneca Ab | Novel Compounds |
WO2004078114A2 (en) | 2003-02-28 | 2004-09-16 | Encysive Pharmaceuticals Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-ii receptor antagonists. |
WO2004078731A1 (fr) * | 2003-03-06 | 2004-09-16 | 'chemical Diversity Research Institute', Ltd. | Acides quinoline-carboxyliques et leurs derives et bibliotheque focalisee |
US7408008B2 (en) | 2003-12-09 | 2008-08-05 | Janssen Pharmaceutica, N.V. | Method of producing highly functionalized 1,3-diamino-propan-2-ols from solid support |
JP2007526324A (ja) | 2004-03-02 | 2007-09-13 | スミスクライン・ビーチャム・コーポレイション | Akt活性のある阻害剤 |
US20050239790A1 (en) | 2004-03-09 | 2005-10-27 | Varghese John | Substituted hydroxyethylamine aspartyl protease inhibitors |
RU2266906C1 (ru) * | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Анелированные карбамоилазагетероциклы, способы их получения (варианты), фармацевтическая композиция, фокусированная библиотека |
WO2005118543A1 (ja) | 2004-06-03 | 2005-12-15 | Ono Pharmaceutical Co., Ltd. | キナーゼ阻害薬およびその用途 |
NZ551603A (en) | 2004-06-24 | 2010-11-26 | Incyte Corp | N-substituted piperidines and their use as pharmaceuticals |
US20060009510A1 (en) | 2004-07-09 | 2006-01-12 | Pharmacia & Upjohn Company Llc | Method of synthesizing indolinone compounds |
JP2008007405A (ja) * | 2004-12-07 | 2008-01-17 | Takeda Chem Ind Ltd | カルボキサミド誘導体 |
WO2007006547A1 (en) | 2005-07-11 | 2007-01-18 | Devgen N.V. | Amide derivatives as kinase inhibitors |
WO2007015805A1 (en) | 2005-07-20 | 2007-02-08 | Eli Lilly And Company | 1-amino linked compounds |
GB0516723D0 (en) | 2005-08-15 | 2005-09-21 | Novartis Ag | Organic compounds |
CA2626549A1 (en) | 2005-10-21 | 2007-04-26 | University Of Alabama At Birmingham | Small molecule inhibitors of hiv-1 capsid assembly |
AU2007221021B2 (en) | 2006-02-28 | 2013-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic piperazines as PDE4 inhibitors |
CA2645556C (en) | 2006-03-16 | 2016-05-24 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
CA2686559A1 (en) | 2006-05-05 | 2007-11-15 | Cambridge Enterprise Limited | Epigenetic regulatory complex for control of gene expression |
EP2394647A1 (en) | 2006-11-02 | 2011-12-14 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain by modulation of glycogenolysis or glycolysis pathways |
CN101012223A (zh) | 2006-11-13 | 2007-08-08 | 西安新安医药科技有限公司 | 用于治疗的奥硝唑衍生物、制备方法及用途 |
JP5542445B2 (ja) | 2006-12-04 | 2014-07-09 | 江▲蘇▼先声▲薬▼物研究有限公司 | 3−ピロロシクロへキシリデン−2−ジヒドロインドリノン誘導体およびその用途 |
CN101157929B (zh) * | 2007-02-02 | 2012-05-23 | 中国科学院上海有机化学研究所 | 番红霉素的生物合成基因簇 |
US20090099157A1 (en) | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
WO2008123582A1 (ja) * | 2007-04-04 | 2008-10-16 | Kowa Company, Ltd. | テトラヒドロイソキノリン化合物 |
DE102007020492A1 (de) | 2007-04-30 | 2008-11-06 | Grünenthal GmbH | Substituierte Sulfonamid-Derivate |
WO2008145398A1 (en) | 2007-06-01 | 2008-12-04 | Pfizer Italia S.R.L. | 4-arylpyrrole substituted 2-indoline derivatives active as protein kinase inhibitors |
JP2010528628A (ja) | 2007-06-07 | 2010-08-26 | シモンズ ハプロミクス リミテッド | エピジェネティック方法 |
WO2008154333A2 (en) | 2007-06-08 | 2008-12-18 | Asuragen, Inc. | Mir-34 regulated genes and pathways as targets for therapeutic intervention |
EP2014651A1 (en) | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
RU2345996C1 (ru) * | 2007-07-17 | 2009-02-10 | Андрей Александрович Иващенко | Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения |
NZ562237A (en) | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
US20090093493A1 (en) | 2007-10-09 | 2009-04-09 | Francesco Berardi | 1-phenylalcoxy-2-beta-phenylethyl derivatives as p-glycoprotein (p-gp) inhibitors useful in drug resistance events |
GB2455176A (en) | 2007-11-01 | 2009-06-03 | Acucela Inc | Amine derivatives useful for treating ophthalmic diseases and disorders |
US8722851B2 (en) | 2007-11-02 | 2014-05-13 | Pain Therapeutics, Inc. | Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
RU2371444C1 (ru) * | 2008-01-24 | 2009-10-27 | Андрей Александрович Иващенко | ФУРО- И ТИЕНО[2,3-b]-ХИНОЛИН-2-КАРБОКСАМИДЫ, СПОСОБ ПОЛУЧЕНИЯ И ПРОТИВОТУБЕРКУЛЕЗНАЯ АКТИВНОСТЬ |
WO2009126782A1 (en) | 2008-04-11 | 2009-10-15 | High Point Pharmaceuticals, Llc | Histamine h3 receptor ligands |
US8791135B2 (en) | 2008-07-01 | 2014-07-29 | Purdue Research Foundation | Nonpeptide HIV-1 protease inhibitors |
FR2933977B1 (fr) * | 2008-07-18 | 2013-04-26 | Centre Nat Rech Scient | Derives heterocycliques utiles dans le traitement des maladies neurodegeneratives |
WO2010028088A2 (en) | 2008-09-05 | 2010-03-11 | Acucela, Inc. | Sulfur-linked compounds for treating opthalmic diseases and disorders |
CA2740952C (en) | 2008-10-22 | 2015-12-29 | Ian L. Scott | Compounds for treating ophthalmic diseases and disorders |
WO2010057101A2 (en) | 2008-11-17 | 2010-05-20 | Schering Corporation | Compounds useful as hiv blockers |
RU2011141794A (ru) | 2009-03-17 | 2013-04-27 | Дайити Санкио Компани, Лимитед | Амидное производное |
US8309547B2 (en) | 2009-04-28 | 2012-11-13 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
CN102573473B (zh) | 2009-06-09 | 2015-05-27 | 加利福尼亚资本权益有限责任公司 | 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物 |
EP2453908B1 (en) | 2009-07-13 | 2018-03-14 | President and Fellows of Harvard College | Bifunctional stapled polypeptides and uses thereof |
GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
EP2357176A1 (en) * | 2010-01-15 | 2011-08-17 | Hybrigenics S.A. | Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
TWI513694B (zh) | 2010-05-11 | 2015-12-21 | Amgen Inc | 抑制間變性淋巴瘤激酶的嘧啶化合物 |
JOP20190250A1 (ar) | 2010-07-14 | 2017-06-16 | Regeneron Pharma | صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب |
WO2012051692A1 (en) | 2010-10-18 | 2012-04-26 | Apotex Pharmachem Inc. | Processes for the preparation of rivaroxaban and intermediates thereof |
EP2630232A4 (en) | 2010-10-22 | 2014-04-02 | Biotime Inc | METHOD FOR MODIFYING TRANSCRIPTIONAL REGULATORY NETWORKS IN STEM CELLS |
US9029343B2 (en) | 2010-12-03 | 2015-05-12 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
BR112013013668A2 (pt) | 2010-12-03 | 2016-09-06 | Epizyme Inc | moduladores 7-deazapurina de histona metiltransferase, e métodos de uso dos mesmos |
CA2826238A1 (en) | 2011-03-25 | 2012-10-04 | Almac Sciences (Scotland) Limited | Enzyme assays |
BR112013027448A2 (pt) | 2011-04-28 | 2020-09-01 | Sloan-Kettering Institute For Cancer Research | terapia de combinação com hsp90 |
US20140294725A1 (en) | 2011-07-08 | 2014-10-02 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
SG11201401222WA (en) | 2011-10-03 | 2014-09-26 | Celmatix Inc | Methods and devices for assessing risk to a putative offspring of developing a condition |
AR092289A1 (es) | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
WO2013098416A2 (fr) | 2011-12-30 | 2013-07-04 | Ecole Nationale Superieure De Chimie De Clermont Ferrand | Composes anti-douleur |
KR101993027B1 (ko) | 2012-04-03 | 2019-09-30 | 레뉴런 리미티드 | 줄기 세포 마이크로입자 |
EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
US20150164955A1 (en) | 2012-07-19 | 2015-06-18 | Reneuron Limited | Stem cell microparticles |
CN104703965A (zh) | 2012-09-25 | 2015-06-10 | 默克专利股份有限公司 | α羟基酰胺 |
KR20230156450A (ko) | 2012-10-15 | 2023-11-14 | 에피자임, 인코포레이티드 | 암을 치료하는 방법 |
EP2925301A4 (en) | 2012-11-29 | 2016-06-01 | Penn State Res Found | THERAPEUTIC PRODUCT AND ANTI-CANCER IMMUNOMODULATOR DHS1P PHOTODYNAMIC |
CA2894130A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof |
US9365555B2 (en) | 2012-12-21 | 2016-06-14 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
JP2016505597A (ja) | 2012-12-21 | 2016-02-25 | エピザイム,インコーポレイティド | Prmt5阻害剤およびその使用 |
EP3498701B1 (en) | 2012-12-21 | 2023-02-22 | Epizyme Inc | Prmt5 inhibitors and uses thereof |
EP2935242A2 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Methods of inhibiting prmt5 |
EP2935240A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
EP2970137A1 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof |
US9133189B2 (en) | 2013-03-14 | 2015-09-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
KR102158756B1 (ko) | 2013-03-14 | 2020-09-23 | 에피자임, 인코포레이티드 | 아르기닌 메틸기 전이효소 억제제 및 이의 용도 |
US9120757B2 (en) | 2013-03-14 | 2015-09-01 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US20160039767A1 (en) | 2013-03-14 | 2016-02-11 | Epizyme, Inc. | Pyrazole derivatives as prmt1 inhibitors and uses thereof |
EP2970131B1 (en) | 2013-03-14 | 2017-11-15 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9023883B2 (en) | 2013-03-14 | 2015-05-05 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
US9447079B2 (en) | 2013-03-14 | 2016-09-20 | Epizyme, Inc. | PRMT1 inhibitors and uses thereof |
EP2970220A2 (en) | 2013-03-14 | 2016-01-20 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US9045455B2 (en) | 2013-03-14 | 2015-06-02 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
KR20160003647A (ko) | 2013-03-15 | 2016-01-11 | 에피자임, 인코포레이티드 | Carm1 억제제 및 이의 용도 |
US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
US9718816B2 (en) | 2013-03-15 | 2017-08-01 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as CARM1 inhibitors and uses thereof |
WO2014177596A1 (en) | 2013-05-03 | 2014-11-06 | F. Hoffmann-La Roche Ag | Neurogenesis-stimulating isoquinoline derivatives |
WO2015200677A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CR20160598A (es) | 2014-06-25 | 2017-03-10 | Glaxosmithkline Intelectual Property Dev Ltd | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il) amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil) pirimidino-4-carboxamida |
EP3160477A4 (en) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
CA2953572A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
WO2016044576A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Salts, co-crystals, amorphous forms, and crystalline forms of an arginine methyltransferase inhibitor |
US20170291905A1 (en) | 2014-09-17 | 2017-10-12 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
US20170283400A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2016044585A1 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Arginine methyltransferase inhibitors and uses thereof |
WO2016044641A2 (en) | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
JP2017527594A (ja) | 2014-09-17 | 2017-09-21 | エピザイム,インコーポレイティド | コアクチベーター関連アルギニンメチルトランスフェラーゼ1(carm1)阻害剤の塩、共結晶、非晶質形態、および結晶形態 |
EP3193608A4 (en) | 2014-09-17 | 2018-05-02 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US20170283440A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
US10487075B2 (en) | 2015-02-11 | 2019-11-26 | Basilea Pharmaceutica International AG | Substituted mono- and polyazanaphthalene derivatives and their use |
WO2017136699A1 (en) | 2016-02-05 | 2017-08-10 | Epizyme, Inc | Arginine methyltransferase inhibitors and uses thereof |
AR108326A1 (es) | 2016-04-27 | 2018-08-08 | Samumed Llc | Isoquinolin-3-il carboxamidas y preparación y uso de las mismas |
GB201704476D0 (en) | 2017-03-21 | 2017-05-03 | Antabio Sas | Chemical compounds |
-
2013
- 2013-12-20 EP EP18192271.7A patent/EP3498701B1/en active Active
- 2013-12-20 SI SI201331283T patent/SI2935222T1/sl unknown
- 2013-12-20 CN CN201380070441.2A patent/CN105452226B/zh active Active
- 2013-12-20 CA CA2894228A patent/CA2894228C/en active Active
- 2013-12-20 KR KR1020157019530A patent/KR102024417B1/ko active IP Right Grant
- 2013-12-20 PL PL13821599T patent/PL2935222T3/pl unknown
- 2013-12-20 PE PE2015001047A patent/PE20151501A1/es unknown
- 2013-12-20 EP EP13821599.1A patent/EP2935222B1/en active Active
- 2013-12-20 BR BR112015014590-6A patent/BR112015014590B1/pt active IP Right Grant
- 2013-12-20 EP EP23156656.3A patent/EP4219465A3/en active Pending
- 2013-12-20 ES ES13821599T patent/ES2701069T3/es active Active
- 2013-12-20 KR KR1020197027023A patent/KR102173874B1/ko active IP Right Grant
- 2013-12-20 MX MX2015008052A patent/MX2015008052A/es active IP Right Grant
- 2013-12-20 EA EA201590975A patent/EA027908B1/ru unknown
- 2013-12-20 JP JP2015549821A patent/JP6678455B2/ja active Active
- 2013-12-20 US US14/654,253 patent/US9604930B2/en active Active
- 2013-12-20 WO PCT/US2013/077235 patent/WO2014100719A2/en active Application Filing
- 2013-12-20 DK DK13821599.1T patent/DK2935222T3/en active
- 2013-12-20 US US14/136,569 patent/US8993555B2/en active Active
- 2013-12-20 RS RS20181485A patent/RS58040B1/sr unknown
- 2013-12-20 PT PT13821599T patent/PT2935222T/pt unknown
- 2013-12-20 HU HUE13821599A patent/HUE040323T2/hu unknown
- 2013-12-20 UA UAA201505700A patent/UA118548C2/uk unknown
- 2013-12-20 LT LTEP13821599.1T patent/LT2935222T/lt unknown
-
2015
- 2015-02-11 US US14/619,371 patent/US9365519B2/en active Active
- 2015-06-09 IL IL239296A patent/IL239296B/en active IP Right Grant
- 2015-06-15 PH PH12015501351A patent/PH12015501351A1/en unknown
- 2015-06-19 CL CL2015001790A patent/CL2015001790A1/es unknown
- 2015-06-19 DO DO2015000158A patent/DOP2015000158A/es unknown
- 2015-07-13 CR CR20150371A patent/CR20150371A/es unknown
- 2015-07-20 ZA ZA2015/05212A patent/ZA201505212B/en unknown
-
2016
- 2016-01-20 HK HK16100586.2A patent/HK1212690A1/zh unknown
- 2016-02-26 US US15/054,193 patent/US9675614B2/en active Active
-
2017
- 2017-01-30 US US15/419,260 patent/US10307413B2/en active Active
- 2017-05-04 US US15/586,775 patent/US20180098987A1/en not_active Abandoned
- 2017-12-15 US US15/844,097 patent/US10391089B2/en active Active
-
2018
- 2018-03-26 AU AU2018202150A patent/AU2018202150B2/en active Active
- 2018-07-30 IL IL260876A patent/IL260876B/en active IP Right Grant
- 2018-12-04 HR HRP20182037TT patent/HRP20182037T1/hr unknown
- 2018-12-05 CY CY20181101294T patent/CY1121625T1/el unknown
-
2019
- 2019-01-23 PH PH12019500163A patent/PH12019500163A1/en unknown
- 2019-04-26 US US16/395,844 patent/US20190343826A1/en not_active Abandoned
- 2019-06-16 IL IL267364A patent/IL267364A/en unknown
- 2019-07-08 US US16/504,910 patent/US10980794B2/en active Active
-
2021
- 2021-03-02 US US17/189,989 patent/US20210308121A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20182037T1 (hr) | Inhibitori prmt5 i njihova uporaba | |
HK1209632A1 (en) | Irak inhibitors and uses thereof -1 (irak) | |
LT2920149T (lt) | 3-aminocikloalkilo junginiai, kaip ror-gama-t inhibitoriai, ir jų panaudojimas | |
HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
EP2890675A4 (en) | GLYCOSIDASE INHIBITORS AND USES THEREOF | |
HK1203949A1 (en) | Inhibitors of iap iap | |
HK1209422A1 (en) | Fbxo3 inhibitors fbxo3 |